Pharmaceutical Company Announces Final Clinical Trial Results For Bipolar Treatment
Encouraged by these results, NRx Pharmaceuticals plans to seek accelerated FDA approval for NRX-101 for patients with bipolar depression at risk of akathisia.
Catching the attention of the pharmaceutical industry and investors alike, NRx Pharmaceuticals (Nasdaq: NRXP), a clinical-stage pharmaceutical company, has announced final clinical trial results showcasing a superior safety profile of NRX-101 over lurasidone in treating suicidal bipolar depression. This announcement, detailed on May 6, 2024, has marked a pivotal moment for NRx Pharmaceuticals, leading to a noteworthy surge in its stock volume by 3.13 and nearing a volume-weighted average price (VWAP) of 6.70. $NRX Pharmaceuticals(NRXP.US$
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
